Mode
Text Size
Log in / Sign up

Inflammatory biomarkers show inconsistent and small associations with antidepressant and ECT treatment response in MDDInflammatory Biomarkers Show Inconsistent Links to Antidepressant Success

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that inconsistent and small effect sizes for inflammatory biomarkers currently preclude their use in guiding MDD treatment.

This umbrella review synthesized evidence regarding the association between inflammatory biomarkers (including CRP, IL-8, TNF-alpha, GM-CSF, IL-5, IL-6, kynurenine, and tryptophan) and treatment response in patients with Major Depressive Disorder (MDD). The review evaluated outcomes for both antidepressant medication and Electroconvulsive Therapy (ECT).

For antidepressant medication, lower baseline CRP and IL-8, along with reductions in TNF-alpha, GM-CSF, and IL-5, were associated with better response in some meta-analyses. However, these findings were noted as inconsistent with generally small effect sizes. Regarding ECT, a single meta-analysis reported only nominally significant associations between higher baseline CRP and IL-6, and lower kynurenine and tryptophan, and greater symptom improvement. Notably, none of these results survived false discovery rate correction.

The authors highlighted several limitations, including inconsistent findings, small effect sizes, and high primary study overlap. Due to these factors, the evidence is currently insufficient to support the clinical use of inflammatory biomarkers to guide treatment decisions for MDD. Clinical application remains limited by the lack of robust, consistent data.

How this fits prior evidence

This umbrella review addresses a gap in understanding the role of inflammatory biomarkers in MDD treatment. While previous coverage established that Electroconvulsive therapy improves symptoms in all age groups of patients with major depressive disorder, this review notes that the association between specific biomarkers and improved ECT outcomes was only nominally significant and did not survive false discovery rate correction. The findings regarding antidepressant response remain inconsistent and small, providing no new evidence to support the use of these biomarkers for clinical decision-making.

This review looked at how certain markers of inflammation in the body, such as CRP and IL-8, relate to treatment success for people with major depressive disorder. Researchers analyzed several meta-analyses to see if these markers could help predict how well a patient might respond to antidepressant medications.

The findings were mixed and the results were generally small. While some studies showed a link between lower levels of certain markers and better responses to antidepressants, the results were not consistent across all studies. Another look at electroconvulsive therapy showed only weak associations with certain markers, which did not hold up well under strict statistical checks.

Because the results are inconsistent and the effects are small, these markers cannot be used to make medical decisions right now. The study also noted that many of the underlying studies overlapped, which can affect the reliability of the data. For now, these findings are not enough to change how doctors choose treatments for depression.

What this means for you:
Current evidence is inconsistent and small, so these markers cannot yet guide treatment for depression.

Common questions

Can these markers tell doctors if my medication will work?

Not yet. The study found that the links between inflammatory markers and treatment response were inconsistent and the effect sizes were small. Because the results are not consistent, these markers cannot be used to guide clinical treatment decisions for patients with major depressive disorder at this time.

What specific markers were studied?

The review looked at several inflammatory biomarkers, including CRP, IL-8, TNF-alpha, GM-CSF, IL-5, IL-6, kynurenine, and tryptophan. While some meta-analyses showed links between lower levels of some of these and better responses, the findings were not strong enough to be used in practice.

What did the study find regarding electroconvulsive therapy?

One meta-analysis looked at electroconvulsive therapy and found only nominally significant associations between certain markers and symptom improvement. These specific results did not survive correction for false discovery rates, meaning the link was not strong enough to be considered reliable.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Major depressive disorder (MDD) is often resistant to standard antidepressant therapy. Inflammation has been implicated in MDD pathophysiology and inflammatory biomarkers have been proposed as predictors of treatment response. This umbrella review synthesises meta-analytic evidence on associations between inflammatory biomarkers and treatment response in MDD. The review followed PRISMA guidelines and was pre-registered on PROSPERO (CRD420251162554). PubMed, Embase, PsycINFO and the Cochrane Database of Systematic Reviews were searched using terms related to depression, treatment response, inflammation and biomarkers. Eligible studies were meta-analyses reporting associations between inflammatory markers and treatment outcomes in MDD. Data were extracted on sample size, effect sizes, heterogeneity, publication bias and conclusions. Methodological quality was assessed using the JBI Critical Appraisal Checklist, and primary study overlap was quantified using the Corrected Covered Area method. Eight meta-analyses met inclusion criteria, covering antidepressant medication and electroconvulsive therapy (ECT). Primary study overlap was 'very high' as measured by the CCA. For antidepressants, lower baseline C-reactive protein (CRP) and interleukin-8 (IL-8), and reductions in tumour necrosis factor-α (TNF-α), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5) during treatment, were associated with better response in some meta-analyses; however, findings were inconsistent and effect sizes generally small. For ECT, a single meta-analysis reported only nominally significant associations between higher baseline CRP and interleukin-6 (IL-6), and lower kynurenine and tryptophan, and greater symptom improvement; none survived false discovery rate correction. Overall, the small effect sizes and inconsistency of findings do not yet support the clinical use of inflammatory biomarkers to guide treatment decisions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.